Background: Targeting antigens to dendritic cell receptors has recently become a popular approach to inducing effective immune responses against cancer antigens. Almost 20 years ago, however, we demonstrated that targeting the mannose receptor on macrophages and dendritic cells leads to strong cellular immune responses. We conducted numerous human clinical trials demonstrating the effectiveness of oxidized mannan-MUC1 (M-FP) in MUC1 + adenocarcinoma patients. In one trial, the 5-8-year follow-up of breast cancer patients vaccinated with M-FP was published previously; we now report here the 12-15-year follow-up. Details regarding the preparation of the vaccine, inclusion and exclusion criteria, immunotherapy and follow-up schedule, were published previously. Results: The follow-up at 12-15 years showed that the recurrence rate in patients receiving placebo was 60% (nine of 15). In those receiving immunotherapy (M-FP), the rate was 12.5% (two of 16). The time of recurrence in the placebo group ranged from 7 to 180 months (mean: 65.8 months) and in the two patients of the vaccine group, the recurrence appeared at 95 and 141 months (mean: 118 months) after surgery. These findings are statistically significant (p = 0.02 for survival and p = 0.009 for percentage of patients cancer-free). All patients injected with M-FP showed no evidence of toxic effects or signs of autoimmunity during the 12-15-year follow-up. Discussion: The preliminary evidence indicates that M-FP is beneficial in the overall survival of early-stage breast cancer patients. This long-term clinical follow-up of patients strongly supports the necessity for a large Phase III study of direct M-FP injection in early-stage breast cancer patients, to evaluate immunotherapy as an adjuvant treatment for breast cancer.
MUC1 is a glycoprotein overexpressed in adenocarcinomas and, in particular, in breast cancer [1, 2] . Over the last 20 years, numerous preclinical studies demonstrated that MUC1 is immunogenic, depending on the MUC1 vaccine formulation. MUC1-based vaccines quickly entered into human clinical trials with immune responses and some clinical responses being reported [3] .
Twenty years ago, we demonstrated that targeting the mannose receptor [4] on macrophages and dendritic cells (DCs) leads to strong Th1 or Th2 cellular and/or humoral immune responses, dependent on the chemical nature of the ligand mannan [5] . Targeting antigens to receptors expressed on DCs, has shown a recent upsurge of interest in developing enhanced vaccines for diseases, including cancer [6, 7] .
We were the first to report that MUC1 was safe in humans as a peptide conjugated to diphtheria toxoid -we soon went into human clinical trials using oxidized mannan-MUC1 (M-FP), which indicated that M-FP was safe in humans and in advanced cancer patients immunity was induced [8, 9 ]. An ex vivo approach using M-FP demonstrated that strong cellular immunity was induced in advanced adenocarcinoma patients [10] . A double-blinded placebo versus M-FP trial was conducted in early breast cancer patients. The 5-8-year follow-up study of early breast cancer patients vaccinated with M-FP was published in 2006 (ISRCTN71711835) [11] . The patients were selected and treated at the Prolipsis Medical Centre (Athens, Greece). M-FP was produced under GLP conditions at the Austin Research Institute (now Burnet Institute; Melbourne, Australia), where the 5-year immunological ana lysis was performed after peripheral blood mononuclear cells and sera were sent from the Prolipsis Medical Centre. The study was initiated once ethics approval had been granted by the National Drug Administration of Greece (EOF; 26 September 1997, no. 27581). The preparation of M-FP, the inclusion and exclusion criteria, the immunotherapy and follow-up schedule and full reference list were previously published [11] . We now report the 12-15-year clinical follow-up of these patients.
Patients & vaccine schedule
The 31 enrolled patients were postmenopausal women treated surgically with or without local radiation for stage II estrogen receptor-positive breast carcinoma, and, no more than four metastatically involved axillary lymph nodes. All patients received adjuvant therapy with tamoxifen 20 mg daily for 5 years. All 31 patients were enrolled in a double-blind study, in which 16 patients had received M-FP and 15 patients had received placebo [11] . All patients' blood samples were taken every 2 weeks, seven times and then at the 6th and 9th month. Follow-up of all the patients was scheduled for clinical and laboratory evaluation every 6 months for 5 years (as previously published), and yearly thereafter for clinical evaluation only, as described herein. In the vaccine M-FP study group of 16 patients, 12 were alive, free of disease; one developed leukemia 118 months after surgery and died 1 year later, without metastatic disease; one developed bone metastases 141 months after surgery, still living with disease; and one developed bone metastases 95 months after surgery and died 14 months later. As reported in our initial paper [11] , nine out of 13 patients who had received M-FP developed anti-MUC1 antibodies -initially IgM, which seroconverted to IgG. Interestingly, patient six, who developed bone metastases 95 months after surgery and died 14 months later, had not developed anti-MUC1 antibodies. In the current follow-up study, we have not measured cellular or humoral immune responses, apart from the initial immunity measured after vaccination. No specific correlation of outcome with immune responses has been measured, however, it was clear from the original publication [11] that, of the patients receiving M-FP, nine of 13 had measurable antibodies to MUC1 and four out of ten had MUC1-specific T-cell responses; none of the placebo-treated patients showed an immune response to MUC1. It is suggestive that humoral and cellular immunity has played a role in the outcome of the vaccinated patients.
In the placebo study group of 15 patients, four were alive free of disease; two were alive free of disease at 120 and 130 months, respectively, after surgery (we are trying to trace them) and nine developed metastatic disease, six of them died and three are still living with disease. As reported in our initial paper [11] , there were no detectable anti-MUC1 antibodies in all 16 patients.
In terms of type and time of recurrences, in the vaccine M-FP study group, two patients developed bone metastases that appeared 95 and 141 months (mean: 118 months) after surgery; in the placebo study group, nine patients developed metastases, four bone, one skin and four visceral -the time of recurrences ranged from 7 to 180 months (mean: 65.8 months) after surgery.
One potential problem with administering a 'self' antigen such as MUC1 is the development of autoimmunity to normal tissues and immune cells expressing MUC1. Surprisingly, this does not appear to be a problem in any of the trials to date, by our group and others [12] [13] [14] [15] [16] . In the current study, no patient at any stage, reported any adverse event; indeed in this and in other studies using M-FP, no adverse events have ever been noted [8] [9] [10] [11] .
Statistical ana lysis of protective efficacy against relapse, was determined by plotting the data for the placebo and M-FP group as Kaplan-Meier survival curves using the PRISM program. All of the patients with relapses and no relapses were analyzed, with time of observation ranging from 132 to 181 months. The placebo and M-FP curves were compared using the log rank test and found to differ significantly with p = 0.02 for survival (Figure 1a) and p = 0.009 for percentage of patients cancer-free (Figure 1b) .
Discussion
The M-FP 'vaccine' appears to confer protection from breast cancer recurrence -both in the short term (5-year follow-up) [11] and, as now shown, in the long term (up to 15-year follow up). Clearly, the M-FP vaccine shows promise and warrants inclusion as a harmless adjuvant therapy, in the current management of patients with breast cancer. The major drawback of the study is the small number of patients in both arms of the study -a large Phase III trial needs to be carried out.
As noted in our 2006 paper [11] and others, oxidized mannan targets the antigen (MUC1) to C-type lectin receptors, including the mannose receptor and, via stimulation of Toll-like receptor-4, of APCs (DCs and macrophages) elicits both T-cell and antibody immunity [17] . Presumably, this immunity removes metastatic cells. Of relevance, we note a study where the occurrence of MUC1 antibodies without future science group future science group immunization in early breast cancer patients (stages I and II) were associated with significant benefit in terms of disease-specific survival [18, 19] . Thus, the presence of antibodies and (T-cell immunity), contribute to the elimination of micrometastasis or early recurrence in breast cancer patients. Evaluation of the immunological treatment, should be taken into consideration of the disease stage. If the disease is in a very-early stage, the risk of recurrence is low and the follow-up time needed for evaluation is long. If the disease is in an advanced stage, then the risk for recurrence is high, but the immunological status of the patient in such a condition will respond poorly.
In this protocol, the patients of the study and placebo group were comparable in stage II where the expected recurrences are approximately 30%, of which 75% will appear within the first 5 years after surgery. In the study group receiving the vaccine, two of 16 patients developed metastases (12.5%). In the placebo group, nine out of 15 patients developed metastases (60%). Furthermore, in the vaccine study group the first metastases appeared 95 months and the second 141 months (mean: 118 months) after surgery, whereas in the placebo group, four out of eight developed metastases within the first 24 months after surgery and five patients developed late metastases after 72 months. The time of recurrence ranged from 7 to 180 months (mean: 51.6 months) after surgery. We note that three of the subjects who appeared to respond to the vaccine (although one subsequently died of leukemia) had lobular cancer, perhaps leading to the suggestion that these cancers may be more responsive than others. However, the numbers are too small to make definitive conclusions, even though lobular carcinomas, will be noted in future studies with larger numbers. When the lobular carcinoma patients were removed from the vaccine group, the statistics were still significant, with p = 0.04 for survival and p = 0.017 for percentage of patients cancer-free. 
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